权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of GIFT4: a B cell focused immunotherapy for cancer

GIFT4 的开发：针对癌症的 B 细胞免疫疗法

基本信息

批准号：
9345070
负责人：
PAUL GUYRE
金额：
$ 99.91万
依托单位：
CELDARA MEDICAL, LLC
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-05-12 至 2019-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9345070
关键词：
Adoptive Cell Transfers Adoptive Transfer Animals Antigen Presentation Autopsy B-Lymphocytes Biological Biological Assay Biological Markers Cancer Model Cancer Patient Cells Clinical Clinical Trials Clonal Expansion Data Development Dose Electrocardiogram Evaluation Excretory function Fermentation Goals Grant Granzyme Guidelines Human Immune Immune checkpoint inhibitor Immune response Immune system Immunologic Surveillance Immunotherapeutic agent Immunotherapy In Vitro Injectable Injection of therapeutic agent Interferon Type II Interleukin-2 Interleukin-6 Investigational Drugs Investigational New Drug Application Malignant Neoplasms Maximum Tolerated Dose Mediating Melanoma Cell Metabolism Minority Modeling Monitor Mus Organ Pathology Patients Phase Phenotype Preparation Process Production Proliferating Property Proteins Protocols documentation Research Resistance development Rodent Safety Small Business Innovation Research Grant Solid Neoplasm System T cell response T-Lymphocyte Testing Toxic effect Toxicology Xenograft procedure Yeasts absorption biomarker identification cancer cell cancer immunotherapy cancer survival chimeric antigen receptor commercialization cytokine efficacy study experimental study flasks granulysin human subject immunogenicity improved in vivo inhibitor/antagonist killings melanoma mouse model neoplastic cell novel partial response preclinical development preclinical safety response safety study tumor tumor growth tumor microenvironment

项目摘要

Project Summary Our goal is to develop a novel immunotherapy for the treatment of melanoma, and potentially a wide array of tumors. Although surveillance by the immune system eliminates cancer cells in some instances, tumor cells have developed a variety of mechanisms to escape immune recognition often resulting in tumor outgrowth. Immune checkpoint inhibitors (e.g. ipilimumab, nivolumab, and pembrolizumab) and cellular immunotherapies (e.g. adoptive cell transfer and CAR (chimeric antigen receptor) T cells) are showing dramatic efficacy in on- going clinical trials. However, even the most promising therapies are effective for a limited range of cancers and only for a minority of patients (e.g. response rates with PD-1 inhibitors are ~25-40%). Moreover, they can be associated with significant toxicities, and tumors – especially solid tumors – eventually develop resistance. The potential of B cells as anti-tumor immunotherapeutics has, to a large extent, remained untapped. Nevertheless, B cells constitute part of the cancer-infiltrating immune cells and they have anti-tumor properties including production of tumor-suppressive cytokines and enhancing tumor-killing T cell response. Indeed, the presence of B cells in the tumor microenvironment is correlated with long-term survival for cancer patients. This application is focused on advancing our preclinical development in preparation for a subsequent Investigational New Drug (IND) application to the FDA. We will determine the optimal efficacious dose of GIFT4 in murine models of cancer; assemble a toxicology package in appropriate models and optimize exprssion and develop fermentation and large-scale purification protocols. Successful commercialization would ultimately provide profound anti-tumor immunotherapeutic benefits in a wide variety of cancer indications, particularly those characterized by a weakened immune system that do not respond to other immunotherapies.

项目总结